Abstract

FORMULATION AND EVALUATION OF OLMESARTAN MEDOXOMIL-LOADED NANOSPONGES FOR HYPERTENSION AND LUNG CANCER TREATMENTS

Shubham N. Thorat* and Tejas D. More

.

Abstract

Olmesartan medoxomil(OLM) is one of the prominent antihypertensive medicine that suffers from low waterless solubility and dissolution rate leading to its low bioavailability. To ameliorate the oral bioavailability of OLM, a delivery system grounded on ethyl cellulose (EC, a biobased polymer) nano sponges (NSs) was developed and estimated for cytotoxicity against the A549 lung cell lines and antihypertensive eventuality in a rat model. Four OLM- loaded NSs (ONS1- ONS4) were prepared and completely estimated in terms of physicochemical parcels. Among these phrasings, ONS4 was regarded as the optimized expression with flyspeck size (487 nm), PDI (0.386), zeta implicit pp. = −18.1 mV), ruse effectiveness (EE = 91.2) and medicine lading (DL = 0.88). In addition, a nanosized pervious morphology was detected for this optimized system with NS face area of about m2/ g, severance volume and severance compass DVD(r) of0.149 cc/ g and15.274 Å, independently, measured by nitrogen adsorption/ desorption analysis. The observed morphology plus sustained release rate of OLM caused that the optimized expression showed advanced cytotoxicity against A549 lung cell lines in comparison to the pure OLM. Eventually, this system (ONS4) reduced the systolic blood pressure (SBP) significantly(p

Keywords: Ethylcellulose; encapsulation; lung cancer; nanosponge; oral bioavailability; systolic blood pressure, Olmesartan.